MD Korczowski Bartosz Gabinet Lekarski
- Address
- lock Available on a paid plan
Digestive System Diseases
At MD Korczowski Bartosz Gabinet Lekarski in Rzeszow, much of the research focuses on digestive system diseases, especially inflammatory bowel disease such as Crohn’s disease and ulcerative colitis. These studies are designed to assess new and existing therapies, with attention to symptom control, remission, and long-term treatment benefit in pediatric patients.
- Testing treatments for Crohn’s disease and ulcerative colitis in children and adolescents
- Evaluating therapies for complex perianal fistulas and other difficult-to-manage bowel complications
- Comparing treatment effectiveness for improving clinical remission and digestive health outcomes
The site is also involved in work on gastroesophageal reflux disease, erosive esophagitis, and related upper digestive conditions, broadening its pediatric gastroenterology research portfolio.
Immune System Diseases
Research in immune system diseases at this pediatric center includes studies in Crohn’s disease, ulcerative colitis, and juvenile psoriatic arthritis. The main goal is to better understand how immune-targeted treatments can reduce inflammation and support sustained disease control in young patients.
- Studying immune-modulating therapies for pediatric inflammatory bowel disease
- Assessing treatment benefit in juvenile psoriatic arthritis
- Monitoring long-term safety and effectiveness of biologic therapies
These trials reflect a strong focus on immune-mediated conditions, with research aimed at improving everyday disease management and reducing the burden of chronic inflammation.
Nutritional and Metabolic Diseases
The site also supports studies in nutritional and metabolic diseases, including obesity or overweight and iron deficiency anemia. This work explores new ways to improve metabolic health and address common pediatric nutritional problems that can affect growth, energy, and overall well-being.
- Evaluating approaches for iron deficiency anemia in children
- Studying treatment strategies related to obesity and weight-related health concerns
- Looking at supportive care for children at risk of nutritional deficiency
This area complements the gastroenterology focus by addressing conditions that often overlap with chronic digestive illness and pediatric health challenges.
Skin and Connective Tissue Diseases
Clinical research in skin and connective tissue diseases includes juvenile psoriatic arthritis, a condition that affects both the joints and the immune system. The studies aim to evaluate how well targeted treatments can improve symptoms, function, and long-term disease control in children.
- Investigating therapies for juvenile psoriatic arthritis
- Assessing disease control in inflammatory conditions affecting the skin and joints
- Supporting research on pediatric autoimmune disease
This research adds an important rheumatologic dimension to the site’s pediatric clinical trial activity.
Immune System Processes
A further area of interest is immune system processes, where studies are examining how inflammation develops and how it can be controlled more effectively. At this site, that research is closely tied to chronic intestinal and autoimmune diseases in children.
- Exploring inflammatory pathways involved in pediatric bowel disease
- Supporting development of treatments that target immune-driven inflammation
- Evaluating whether therapies can improve remission and reduce disease activity
Overall, the research profile at MD Korczowski Bartosz Gabinet Lekarski centers on helping children with chronic immune-related conditions through studies of treatment effectiveness, safety, and long-term disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Janssen Cilag International2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MD Korczowski Bartosz Gabinet Lekarski
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Gastritis with or without Eosinophilic Duodenitis | Regeneron Pharmaceuticals Inc. | Phase II | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vedolizumab | 4 | Unknown | 2018-01-09 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
